Oncogenic ERBB3 mutations in human cancers - PubMed (original) (raw)
. 2013 May 13;23(5):603-17.
doi: 10.1016/j.ccr.2013.04.012.
Noelyn M Kljavin, Eric W Stawiski, Emily Chan, Chaitali Parikh, Steffen Durinck, Subhra Chaudhuri, Kanan Pujara, Joseph Guillory, Kyle A Edgar, Vasantharajan Janakiraman, Rolf-Peter Scholz, Krista K Bowman, Maria Lorenzo, Hong Li, Jiansheng Wu, Wenlin Yuan, Brock A Peters, Zhengyan Kan, Jeremy Stinson, Michelle Mak, Zora Modrusan, Charles Eigenbrot, Ron Firestein, Howard M Stern, Krishnaraj Rajalingam, Gabriele Schaefer, Mark A Merchant, Mark X Sliwkowski, Frederic J de Sauvage, Somasekar Seshagiri
Affiliations
- PMID: 23680147
- DOI: 10.1016/j.ccr.2013.04.012
Free article
Oncogenic ERBB3 mutations in human cancers
Bijay S Jaiswal et al. Cancer Cell. 2013.
Free article
Erratum in
- Cancer Cell. 2014 Apr 14;25(4):543-4
Abstract
The human epidermal growth factor receptor (HER) family of tyrosine kinases is deregulated in multiple cancers either through amplification, overexpression, or mutation. ERBB3/HER3, the only member with an impaired kinase domain, although amplified or overexpressed in some cancers, has not been reported to carry oncogenic mutations. Here, we report the identification of ERBB3 somatic mutations in ~11% of colon and gastric cancers. We found that the ERBB3 mutants transformed colonic and breast epithelial cells in a ligand-independent manner. However, the mutant ERBB3 oncogenic activity was dependent on kinase-active ERBB2. Furthermore, we found that anti-ERBB antibodies and small molecule inhibitors effectively blocked mutant ERBB3-mediated oncogenic signaling and disease progression in vivo.
Copyright © 2013 Elsevier Inc. All rights reserved.
Similar articles
- Regulation of ERBB3/HER3 signaling in cancer.
Mujoo K, Choi BK, Huang Z, Zhang N, An Z. Mujoo K, et al. Oncotarget. 2014 Nov 15;5(21):10222-36. doi: 10.18632/oncotarget.2655. Oncotarget. 2014. PMID: 25400118 Free PMC article. Review. - APIP, an ERBB3-binding partner, stimulates erbB2-3 heterodimer formation to promote tumorigenesis.
Hong SH, Lee WJ, Kim YD, Kim H, Jeon YJ, Lim B, Cho DH, Heo WD, Yang DH, Kim CY, Yang HK, Yang JK, Jung YK. Hong SH, et al. Oncotarget. 2016 Apr 19;7(16):21601-17. doi: 10.18632/oncotarget.7802. Oncotarget. 2016. PMID: 26942872 Free PMC article. - Loss of Nrdp1 enhances ErbB2/ErbB3-dependent breast tumor cell growth.
Yen L, Cao Z, Wu X, Ingalla ER, Baron C, Young LJ, Gregg JP, Cardiff RD, Borowsky AD, Sweeney C, Carraway KL 3rd. Yen L, et al. Cancer Res. 2006 Dec 1;66(23):11279-86. doi: 10.1158/0008-5472.CAN-06-2319. Cancer Res. 2006. PMID: 17145873 - Functional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells.
Kim A, Liu B, Ordonez-Ercan D, Alvarez KM, Jones LD, McKimmey C, Edgerton SM, Yang X, Thor AD. Kim A, et al. Breast Cancer Res. 2005;7(5):R708-18. doi: 10.1186/bcr1281. Epub 2005 Jul 6. Breast Cancer Res. 2005. PMID: 16168116 Free PMC article. - Role of erbB3 receptors in cancer therapeutic resistance.
Lee Y, Ma J, Lyu H, Huang J, Kim A, Liu B. Lee Y, et al. Acta Biochim Biophys Sin (Shanghai). 2014 Mar;46(3):190-8. doi: 10.1093/abbs/gmt150. Epub 2014 Jan 20. Acta Biochim Biophys Sin (Shanghai). 2014. PMID: 24449784 Review.
Cited by
- Germline single nucleotide polymorphisms in ERBB3 and BARD1 genes result in a worse relapse free survival response for HER2-positive breast cancer patients treated with adjuvant based docetaxel, carboplatin and trastuzumab (TCH).
Coté D, Eustace A, Toomey S, Cremona M, Milewska M, Furney S, Carr A, Fay J, Kay E, Kennedy S, Crown J, Hennessy B, Madden S. Coté D, et al. PLoS One. 2018 Aug 2;13(8):e0200996. doi: 10.1371/journal.pone.0200996. eCollection 2018. PLoS One. 2018. PMID: 30071039 Free PMC article. Clinical Trial. - Detection of gene mutations in gastric cancer tissues using a commercial sequencing panel.
Ito T, Matoba R, Maekawa H, Sakurada M, Kushida T, Orita H, Wada R, Sato K. Ito T, et al. Mol Clin Oncol. 2019 Nov;11(5):455-460. doi: 10.3892/mco.2019.1926. Epub 2019 Sep 24. Mol Clin Oncol. 2019. PMID: 31620276 Free PMC article. - Mechanisms Underlying the Action and Synergism of Trastuzumab and Pertuzumab in Targeting HER2-Positive Breast Cancer.
Nami B, Maadi H, Wang Z. Nami B, et al. Cancers (Basel). 2018 Sep 20;10(10):342. doi: 10.3390/cancers10100342. Cancers (Basel). 2018. PMID: 30241301 Free PMC article. Review. - Integrative Kinome Profiling Identifies mTORC1/2 Inhibition as Treatment Strategy in Ovarian Clear Cell Carcinoma.
Caumanns JJ, Berns K, Wisman GBA, Fehrmann RSN, Tomar T, Klip H, Meersma GJ, Hijmans EM, Gennissen AMC, Duiker EW, Weening D, Itamochi H, Kluin RJC, Reyners AKL, Birrer MJ, Salvesen HB, Vergote I, van Nieuwenhuysen E, Brenton J, Braicu EI, Kupryjanczyk J, Spiewankiewicz B, Mittempergher L, Bernards R, van der Zee AGJ, de Jong S. Caumanns JJ, et al. Clin Cancer Res. 2018 Aug 15;24(16):3928-3940. doi: 10.1158/1078-0432.CCR-17-3060. Epub 2018 Apr 23. Clin Cancer Res. 2018. PMID: 29685880 Free PMC article. - Molecular Correlates of In Vitro Responses to Dacomitinib and Afatinib in Bladder Cancer.
Tamura S, Wang Y, Veeneman B, Hovelson D, Bankhead A 3rd, Broses LJ, Lorenzatti Hiles G, Liebert M, Rubin JR, Day KC, Hussain M, Neamati N, Tomlins S, Palmbos PL, Grivas P, Day ML. Tamura S, et al. Bladder Cancer. 2018 Jan 20;4(1):77-90. doi: 10.3233/BLC-170144. Bladder Cancer. 2018. PMID: 29430509 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
Research Materials
Miscellaneous